PERFLUTREN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C3F8
Molecular Weight	188.0193
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)C(F)(F)C(F)(F)F

InChI

InChIKey=QYSGYZVSCZSLHT-UHFFFAOYSA-N

InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11

HIDE SMILES / InChI

Molecular Formula	C3F8
Molecular Weight	188.0193
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB00556 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf

Perflutren is a diagnostic drug that is used for the contrast enhancement during echocardiographic. It consists of lipid-coated microspheres filled with octafluoropropane gas. Ultrasound waves make the microspheres resonate and reflect a strong signal to an ultrasound machine. This results in a difference of density between gas-filled bubbles and blood around them and improves contrast of resulting images. Perflutren is used in patients with suboptimal echocardiograms to opacify the left ventricular chamber and improve the delineation of the heart borders.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Heart Diseases 2 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a&type=display https://www.drugbank.ca/drugs/DB00556	Diagnostic		Approved 8583	DEFINITY Approved Use DEFINITY is an ultrasound contrast agent indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. Launch Date 2001

Doses

Dose	Population	Adverse events
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf	unhealthy, 18 - 93 Health Status: unhealthy Age Group: 18 - 93 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf	Disc. AE: Urticaria, Pruritus... AEs leading to discontinuation/dose reduction: Urticaria Pruritus Dizziness Chest pain Dyspnea Back pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf	Disc. AE: Cardiac arrest, Respiratory arrest... AEs leading to discontinuation/dose reduction: Cardiac arrest (grade 5) Respiratory arrest (grade 5) Shock (serious) Syncope (serious) Arrhythmia (serious) Hypertension (serious) Hypotension (serious) Dyspnea (serious) Hypoxia (serious) Chest pain (serious) Respiratory distress (serious) Stridor (serious) Wheezing (serious) Loss of consciousness (serious) Convulsions (serious) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf	Disc. AE: Anaphylactoid reaction... AEs leading to discontinuation/dose reduction: Anaphylactoid reaction (serious) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf

AEs

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY456877	https://www.001chemical.com/chem/76-19-7
3B Scientific (Wuhan) Corp	3B3-051504	http://www.3bsc.com/index/pro_info.php?id=89205
abcr GmbH	AB104454	http://www.abcr.com/shop/en/AB104454
abcr GmbH	AB128946	http://www.abcr.de/shop/en/AB128946
Aceschem	ACF024078	https://www.aceschem.com/catalog/76-19-7.html
AHH Chemical co.,ltd	MT-20856	http://www.ahhchemical.com/product/MT-20856.html
Ambinter	Amb10840757	http://www.ambinter.com/reference/10840757
Angene	AGN-PC-0JK7KY	http://www.angenechemical.com/productshow/AGN-PC-0JK7KY.html
Avantor Inc	101178-534	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101178-534
Avantor Inc	200004-456	https://us.vwr.com/store/product/18604304/bovine-serum-albumin-bsa-lyophilized-powder-acros-organics
Avantor Inc	700011-226	https://us.vwr.com/store/product/7829013/bovine-serum-albumin-bsa-spectrum-chemical
Avantor Inc	700011-228	https://us.vwr.com/store/product/7829013/bovine-serum-albumin-bsa-spectrum-chemical
Avantor Inc	700011-230	https://us.vwr.com/store/product/7829027/bovine-serum-albumin-bsa-spectrum-chemical
BOC Sciences	9048-46-8	https://www.bocsci.com/albumin-from-bovine-serum-cas-9048-46-8-item-382204.html
ChemFish Tokyo co.,ltd	6432	http://www.chemfish.com/
ChemMol	49416688	http://www.chemmol.com/chemmol/49416688.html
ChemMol	49423611	http://www.chemmol.com/chemmol/49423611.html
ChemMol	99147238	http://www.chemmol.com/chemmol/99147238.html
Debye Scientific	DB-056033	http://www.debyesci.com/cas_76-19-7.html
eNovation Chemicals	D628372	https://www.enovationchem.com/ProductDetails.asp?ProductID=D628372
Finetech	FT-0621948	http://www.finetechnology-ind.com/prod/detail/pub/70024-90-7.html
Finetech	FT-0631321	http://www.finetechnology-ind.com/prod/detail/pub/76-19-7.html
iChemical	EBD3015254	http://www.ichemical.com/products/9048-46-8.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
iChemical	EBD34753	http://www.ichemical.com/products/76-19-7.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Molcore	MC456877	https://www.molcore.com/product/76-19-7
Smolecule	S539039	http://www.smolecule.com/products/s539039
THE BioTek	bt-278563	https://www.thebiotek.com/product/inhibitors/bt-278563
VladaChem	VL260738-1G	https://www.vladachem.com/product.php?products=9048-46-8
VladaChem	VL279346-100G	https://www.vladachem.com/product.php?products=9048-46-8

PubMed

Title	Date	PubMed
Inverted pneumatic retinopexy.	2003-11	14597545
Inverted pneumatic retinopexy.	2003-11	14597544
Vitrectomy with indocyanine green-guided inner limiting membrane peeling for a Q-switched Nd:YAG laser-induced macular hole.	2003-10	14574262
Perfluorocarbon liquid utilization in primary vitrectomy repair of retinal detachment with multiple breaks.	2003-10	14574244
Early macular holes with retinoschisis in highly myopic eyes.	2003-10	14516820
Comparison of scleral buckling with combined scleral buckling and pars plana vitrectomy in the management of rhegmatogenous retinal detachment with unseen retinal breaks.	2003-10	14516427
Better success of retinal reattachment with long-standing gas tamponade in highly myopic eyes.	2003-10	12942239
Real-time assessment of myocardial perfusion during balloon angioplasty of the left anterior descending coronary artery.	2003-09-15	12972101
Comparison of intravenous myocardial contrast echocardiography and low-dose dobutamine echocardiography for predicting left ventricular functional recovery following acute myocardial infarction.	2003-09-01	12943867
Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets in vitro.	2003-09	14553814
Extra-low acoustic power harmonic images of the liver with perflutren: novel imaging for real-time observation of liver perfusion.	2003-09	14510264
A pilot study of pars plana vitrectomy, intraocular gas, and radial neurotomy in ischaemic central retinal vein occlusion.	2003-09	12928281
Management of retinal detachment in osteogenesis imperfecta.	2003-07	12860823
Influence of contrast ultrasonography with perflutren lipid microspheres on microvessel injury.	2003-07	12845189
Vitrectomy with internal limiting membrane peeling for macular retinoschisis and retinal detachment without macular hole in highly myopic eyes.	2003-07	12834688
Repair of late Descemet's membrane detachment with perfluoropropane gas.	2003-06	12842700
Comparison of silicone oil versus gas tamponade in the treatment of idiopathic full-thickness macular hole.	2003-06	12799243
Topical medication interferes with face-down positioning after macular hole surgery.	2003-06	12780398
Contrast echocardiography using intravenous octafluoropropane and real-time perfusion imaging predicts functional recovery after acute myocardial infarction.	2003-06	12778024
Intestinal and hepatic lesions in mice, rats, and other laboratory animals after intravenous administration of gas-carrier contrast agents used in ultrasound imaging.	2003-05-01	12729716
The behaviour of individual contrast agent microbubbles.	2003-05	12754068
Macular hole secondary to fungal endophthalmitis.	2003-05	12742858
Long-term anatomic and visual acuity outcomes after initial anatomic success with macular hole surgery.	2003-05	12719070
Lower receiving frequencies than transmitting frequencies could yield improved results for contrast imaging: an in vivo study in closed chest canines.	2003-04	12848663
Microbubble-augmented ultrasound declotting of thrombosed arteriovenous dialysis grafts in dogs.	2003-03	12631639
Inverted pneumatic retinopexy: a method of treating retinal detachments associated with inferior retinal breaks.	2003-03	12623827
Anatomic and functional results of vitrectomy and long-term intraocular tamponade for stage 2 macular holes.	2003-02	12652232
Indocyanine green assisted retinal internal limiting membrane removal in stage 3 or 4 macular hole surgery.	2003-01	12488266
Understanding the limitations of ultrasonic backscatter measurements from microbubble populations.	2002-12-07	12502050
Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model.	2002-12	12625773
Management of submacular hemorrhage.	2002-12	12515076
Intravitreal gas injection for the treatment of experimental vitreous hemorrhage in rabbits.	2002-11	12658544
Evaluation of posturing in macular hole surgery.	2002-11	12439662
Ultrasound increases plasmid-mediated gene transfer to dystrophic muscles without collateral damage.	2002-11	12436962
Loss of vision caused by expansion of intraocular perfluoropropane (C(3)F(8)) gas during nitrous oxide anesthesia.	2002-11	12429255
Combined perfluoropropane gas and viscoelastic material injection for anterior chamber reformation following trabeculectomy.	2002-11	12386073
A biological model of tamponade gases following pneumatic retinopexy.	2002-10	12658552
Complications of general anesthesia using nitrous oxide in eyes with preexisting gas bubbles.	2002-10	12441721
Central retinal artery occlusion caused by expansion of intraocular gas at high altitude.	2002-10	12383821
Nitrous oxide anaesthesia in the presence of intraocular gas can cause irreversible blindness.	2002-09-07	12217995
Angle closure glaucoma following pupillary block in an aphakic perfluoropropane gas-filled eye.	2002-09	12355700
Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome.	2002-09	12271367
Bioeffects of myocardial contrast microbubble destruction by echocardiography.	2002-08	12356345
Phacovitrectomy with internal limiting membrane peeling for idiopathic macular hole.	2002-08	12322859
Pressure-dependent attenuation in ultrasound contrast agents.	2002-08	12217440
Effects of Optison on pulmonary gas exchange and hemodynamics.	2002-08	12217436
Automated endocardial border detection and evaluation of left ventricular function from contrast-enhanced images using modified acoustic quantification.	2002-08	12174346
Effects of preoperative and postoperative epiretinal membranes on macular hole closure and visual restoration.	2002-08	12153804
The dependence of ultrasound contrast agents backscatter on acoustic pressure: theory versus experiment.	2002-05	12160005
Results of vitrectomy and the no-touch-technique using autologous adjuvants in macular hole treatment.	2001	12498512

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:32:08 GMT 2025` Edited by `admin` on `Mon Mar 31 18:32:08 GMT 2025`
Record UNII	CK0N3WH0SR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PERFLUTREN

Official Name

English

Octafluoropropane

Preferred Name

English

LUMINITY

Brand Name

English

DMP115

Code

English

OCTAFLUORO-PROPANE

Systematic Name

English

PERFLUTREN [EMA EPAR]

Common Name

English

PERFLUOROPROPANE

Systematic Name

English

PERFLUTREN [VANDF]

Common Name

English

OCTAFLUOROPROPANE [VANDF]

Common Name

English

PERFLUOROPROPANE [MI]

Common Name

English

1,1,1,2,2,3,3,3-OCTAFLUOROPROPANE

Systematic Name

English

OPTISON

Brand Name

English

FS069

Code

English

OXTAFLUOROPROPANE [VANDF]

Common Name

English

PERFLUTREN [ORANGE BOOK]

Common Name

English

PROPANE, OCTAFLUORO-

Systematic Name

English

DMP-115

Code

English

perflutren [INN]

Common Name

English

Perflutren [WHO-DD]

Common Name

English

PERFLUTREN [USAN]

Common Name

English

FS-069

Code

English

PERFLUTREN [MART.]

Common Name

English

MRX-115

Code

English

DEFINITY

Brand Name

English

PERFLUTREN [II]

Common Name

English

PERFLUTREN [JAN]

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

LUMINITY (AUTHORIZED: ECHOCARDIOGRAPHY)